Gadolinium Contrast Agents for CNS Imaging: Current Concepts and Clinical Evidence

Overview

Journal AJNR Am J Neuroradiol

Specialty Neurology

Date 2014 May 24

PMID 24852287

Citations 30

Authors

E Kanal

K Maravilla

H A Rowley

Affiliations

Soon will be listed here.

Abstract

The aim of this article was to review the properties of the various gadolinium-based contrast agents used for CNS imaging along with the clinical evidence and published data that highlight the impact these different properties can have on diagnostic performance. In addition, approaches to optimizing image acquisition that take into account the different properties of specific gadolinium-based contrast agents and an extensive review of the safety profiles of the various agents are presented.

Citing Articles

Evolving Characteristics of Gadolinium-Based Contrast Agents for MR Imaging: A Systematic Review of the Importance of Relaxivity.

Kanal E, Maki J, Schramm P, Marti-Bonmati L J Magn Reson Imaging. 2024; 61(1):52-69.

PMID: 38699938 PMC: 11645498. DOI: 10.1002/jmri.29367.

Improved reproducibility for myocardial ASL: Impact of physiological and acquisition parameters.

Bozic-Iven M, Rapacchi S, Tao Q, Pierce I, Thornton G, Nitsche C Magn Reson Med. 2023; 91(1):118-132.

PMID: 37667643 PMC: 10962577. DOI: 10.1002/mrm.29834.

Current practices and perspectives on the integration of contrast agents in MRI-guided radiation therapy clinical practice: A worldwide survey.

Boldrini L, Alongi F, Romano A, Charles Davies D, Bassetti M, Chiloiro G Clin Transl Radiat Oncol. 2023; 40:100615.

PMID: 36968577 PMC: 10034422. DOI: 10.1016/j.ctro.2023.100615.

The TRUTH confirmed: validation of an intraindividual comparison of gadobutrol and gadoteridol for imaging of glioblastoma using quantitative enhancement analysis.

Kuhn M, Patriarche J, Patriarche D, Kirchin M, Bona M, Pirovano G Eur Radiol Exp. 2021; 5(1):46.

PMID: 34635965 PMC: 8505590. DOI: 10.1186/s41747-021-00240-2.

Diffusion Tensor Imaging of the Dentate Nucleus After Repeated Administration of Gadobutrol in Children.

Ozturk K, Nascene D Cerebellum. 2021; 21(4):657-664.

PMID: 34453283 DOI: 10.1007/s12311-021-01324-w.

References

Maravilla K, Maldjian J, Schmalfuss I, Kuhn M, Bowen B, Wippold 2nd F . Contrast enhancement of central nervous system lesions: multicenter intraindividual crossover comparative study of two MR contrast agents. Radiology. 2006; 240(2):389-400. DOI: 10.1148/radiol.2402051266. View

Akeson P, Jonsson E, Haugen I, Holtas S . Contrast-enhanced MRI of the central nervous system: comparison between gadodiamide injection and gadolinium-DTPA. Neuroradiology. 1995; 37(3):229-33. DOI: 10.1007/BF01578263. View

Semelka R, Hernandes M, Stallings C, Castillo M . Objective evaluation of acute adverse events and image quality of gadolinium-based contrast agents (gadobutrol and gadobenate dimeglumine) by blinded evaluation. Pilot study. Magn Reson Imaging. 2012; 31(1):96-101. DOI: 10.1016/j.mri.2012.06.025. View

Griffiths P, Wilkinson I, Wels T, Hoggard N . Brain MR perfusion imaging in humans. Acta Radiol. 2001; 42(6):555-9. View

Yuh W, Fisher D, Engelken J, Greene G, Sato Y, Ryals T . MR evaluation of CNS tumors: dose comparison study with gadopentetate dimeglumine and gadoteridol. Radiology. 1991; 180(2):485-91. DOI: 10.1148/radiology.180.2.2068317. View

Idee J, Port M, Robic C, Medina C, Sabatou M, Corot C . Role of thermodynamic and kinetic parameters in gadolinium chelate stability. J Magn Reson Imaging. 2009; 30(6):1249-58. DOI: 10.1002/jmri.21967. View

Knopp M, Runge V, Essig M, Hartman M, Jansen O, Kirchin M . Primary and secondary brain tumors at MR imaging: bicentric intraindividual crossover comparison of gadobenate dimeglumine and gadopentetate dimeglumine. Radiology. 2003; 230(1):55-64. DOI: 10.1148/radiol.2301021085. View

Shellock F, Parker J, Pirovano G, Shen N, Venetianer C, Kirchin M . Safety characteristics of gadobenate dimeglumine: clinical experience from intra- and interindividual comparison studies with gadopentetate dimeglumine. J Magn Reson Imaging. 2006; 24(6):1378-85. DOI: 10.1002/jmri.20764. View

Prokop M, Schneider G, Vanzulli A, Goyen M, Ruehm S, Douek P . Contrast-enhanced MR Angiography of the renal arteries: blinded multicenter crossover comparison of gadobenate dimeglumine and gadopentetate dimeglumine. Radiology. 2004; 234(2):399-408. DOI: 10.1148/radiol.2342040023. View

10.

Schiavino D, Murzilli F, Del Ninno M, Buonomo A, Roncallo C, Pollastrini E . Demonstration of an IgE-mediated immunological pathogenesis of a severe adverse reaction to gadopentetate dimeglumine. J Investig Allergol Clin Immunol. 2003; 13(2):140-2. View

11.

Wang J, Yan F, Liu J, Lu J, Li D, Luan J . Multicenter, intra-individual comparison of single dose gadobenate dimeglumine and double dose gadopentetate dimeglumine for MR angiography of the peripheral arteries (the Peripheral VALUE Study). J Magn Reson Imaging. 2013; 38(4):926-37. DOI: 10.1002/jmri.24040. View

12.

Abujudeh H, Kosaraju V, Kaewlai R . Acute adverse reactions to gadopentetate dimeglumine and gadobenate dimeglumine: experience with 32,659 injections. AJR Am J Roentgenol. 2010; 194(2):430-4. DOI: 10.2214/AJR.09.3099. View

13.

Colosimo C, Ruscalleda J, Korves M, Ferla R, Wool C, Pianezzola P . Detection of intracranial metastases: a multicenter, intrapatient comparison of gadobenate dimeglumine-enhanced MRI with routinely used contrast agents at equal dosage. Invest Radiol. 2001; 36(2):72-81. DOI: 10.1097/00004424-200102000-00002. View

14.

Forsting M, Palkowitsch P . Prevalence of acute adverse reactions to gadobutrol--a highly concentrated macrocyclic gadolinium chelate: review of 14,299 patients from observational trials. Eur J Radiol. 2009; 74(3):e186-92. DOI: 10.1016/j.ejrad.2009.06.005. View

15.

Anzalone N, Gerevini S, Scotti R, Vezzulli P, Picozzi P . Detection of cerebral metastases on magnetic resonance imaging: intraindividual comparison of gadobutrol with gadopentetate dimeglumine. Acta Radiol. 2009; 50(8):933-40. DOI: 10.1080/02841850903095385. View

16.

Prince M, Zhang H, Zou Z, Staron R, Brill P . Incidence of immediate gadolinium contrast media reactions. AJR Am J Roentgenol. 2011; 196(2):W138-43. DOI: 10.2214/AJR.10.4885. View

17.

Rohrer M, Bauer H, Mintorovitch J, Requardt M, Weinmann H . Comparison of magnetic properties of MRI contrast media solutions at different magnetic field strengths. Invest Radiol. 2005; 40(11):715-24. DOI: 10.1097/01.rli.0000184756.66360.d3. View

18.

Myhr G, Rinck P, Borseth A . Gadodiamide injection and gadopentetate dimeglumine. A double-blind study in MR imaging of the CNS. Acta Radiol. 1992; 33(5):405-9. View

19.

Grossman R, Rubin D, Hunter G, Haughton V, Lee D, Sze G . Magnetic resonance imaging in patients with central nervous system pathology: a comparison of OptiMARK (Gd-DTPA-BMEA) and Magnevist (Gd-DTPA). Invest Radiol. 2000; 35(7):412-9. DOI: 10.1097/00004424-200007000-00003. View

20.

Cochran S, Bomyea K, Sayre J . Trends in adverse events after IV administration of contrast media. AJR Am J Roentgenol. 2001; 176(6):1385-8. DOI: 10.2214/ajr.176.6.1761385. View